,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Ms. Lisa A. Conte', 'age': 63, 'title': 'Founder, CEO, Pres & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 771398, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
1,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Dr. Pravin R. Chaturvedi Ph.D.', 'age': 59, 'title': 'Chief Scientific Officer & Chair of Scientific Advisory Board', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 539042, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
2,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Mr. Jonathan S. Wolin CPA, J.D., M.B.A.', 'age': 59, 'title': 'Chief of Staff, Chief Compliance Officer & Gen. Counsel', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 520292, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
3,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Mr. Ian H. Wendt M.B.A.', 'age': 54, 'title': 'Chief Commercial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 441310, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
4,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Dr. Steven R. King Ph.D.', 'age': 64, 'title': 'Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 477658, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
5,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Ms. Carol R. Lizak M.B.A.', 'age': 58, 'title': 'Chief Financial Officer', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
6,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Mr. Peter  Hodge', 'title': 'Sr. Director of Investor Relations, Bus. Devel. & Special Events', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
7,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Dr. Karen J. Brunke Ph.D.', 'age': 69, 'title': 'Exec. VP of Corp. & Bus. Devel.', 'yearBorn': 1953, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
8,200 Pine Street,Suite 400,San Francisco,CA,94104,United States,415 371 8300,https://jaguar.health,Biotechnology,Biotechnology,Healthcare,Healthcare,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.",60,"{'maxAge': 1, 'name': 'Mr. David  Sesin', 'title': 'Chief Manufacturing Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.308,0.31,0.28,0.3163,0.308,0.31,0.28,0.3163,0.0,1.87621,-0.53865385,1072841,1072841,804908,1076080,1076080,0.29,0.2933,1800,1200,5354727,0.28,16.05,0.48424008,0.4932,2.32956,0.0,0.0,USD,28581734,0.0,13900895,19117200,581064,555590,1690761600,1693440000,0.0304,0.17668,0.02049,0.94,0.0304,19117200,0.295,0.9494915,1672444800,1703980800,1688083200,-44453000,-7.19,-0.52,0.0,1:75,1674432000,2.585,-0.89,-0.98035085,0.14113986,NCM,EQUITY,JAGX,JAGX,"Jaguar Health, Inc.","Jaguar Health, Inc.",1431437400,America/New_York,EDT,44b69c61-ddb7-3614-b68e-0fb78489f0ca,finmb_12827020,-14400000,0.2801,6.0,6.0,6.0,6.0,1.0,strong_buy,1,8627000,0.451,-32125000,31663000,0.351,0.973,11058000,543.291,1.688,-0.41801,-10.60664,-18280000,-33953000,-0.084,0.8242,-2.9051402,-3.08636,USD,
